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CA1
ECONOMIC ANALYSIS OF IMPLANTABLE CARDIOVERTER
DEFIBRILLATORS INTHE PRIMARY PREVENTION OF SUDDEN
CARDIAC DEATH—A CANADIAN PERSPECTIVE
Deniz B1, Sadri H2
1United BioSource Corporation, Concord, MA, USA, 2Medtronic of
Canada Ltd,Toronto, ON, Canada
OBJECTIVE: To conduct a cost-beneﬁt analysis (CB) for the
Implantable Cardioverter Deﬁbrillators (ICDs) in the primary
prevention of Sudden Cardiac Death (SCD) compared to amio-
darone. METHODS: A discrete event simulation model was built
to determine the cost-beneﬁt ratio associated with ICDs from a
societal perspective in Canada using the “value of life” approach
as a measure of “beneﬁt”. The clinical inputs were derived from
the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
and the Amiodarone Trial Analysis (ATMA) studies. The related
costs were derived from the Ontario Health Insuranace Plans’
(OHIP) schedule of beneﬁts and fees, Ontario Drug Beneﬁt for-
mulary (ODB) and published data. The value of life in Canada
(CND$5.8Mil.), as determined by Health Canada, was used in
the model. One hundred replicaitons of 1000 identical twin pairs
over 7 years, aligned with the average life of an ICD, were run.
The costs (year 2006) and outcomes ere discounted at 3%.
Sensitivity Analysis (SAs) were performed for key input param-
eters. RESULTS: The absolute all-cause mortality was reduced by
eight percent with ICD over seven years compared to amio-
darone. The average costs associated with ICD and amiodarone
treatments were estimated as CND$32,000 and CND$6400 per
patient, respectively. The predicted cost-beneﬁt ratio (CBR) was
0.04. This ﬁgure suggests that for every $1 spent for ICD in the
primary prevention of SCD the society will gain $25 in “value”
by human lives saved. SAs showed that results were robust (CBR:
0.035–0.044). CONCLUSION: IDs reduce the risk of SCD due
to arrhythmia compared to amiodarone. The estimated CBR
suggests that ICDs are worthwhile investment from a societal
perspective in Canada. The initial investment for ICD in primary
prevention of SCD in Canada is comparable and in many cases
lower when compared to other societal programs for saving lives.
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THE USE OF RESEARCH ABSTRACTS IN FORMULARY
DECISION MAKING BYTHE ONTARIO CANCER DRUG
APPROVAL COMMITTEE
Weizman A1, Bell C2
1University of Toronto,Toronto, Ontario, Canada, 2Department of
Medicine, St. Michael’s Hospital,Toronto, ON, Canada
OBJECTIVE: To evaluate the inﬂuence of research abstracts in
guiding evidence based decisions of the Ontario Cancer Drug
Approval Committee. METHODS: The Ontario Cancer Drug
Approval Committee is a joint initiative between the Ontario
Ministry of Health and Cancer Care Ontario that provides a
clinical and economic evaluation process for new cancer-related
drugs for formulary listing consideration. The minutes of the
monthly committee meetings between 2005 and 2007 were
reviewed. One submission per drug indication was included.
Elements from the decisions were entered into a database which
included the level of evidence supporting each decision, the loca-
tion from which the evidence originated, and the year the litera-
ture was produced. An abstract was deﬁned as anything in the
evidentiary base that was unpublished or was clearly deﬁned as
an abstract in the meeting minutes. RESULTS: There were
62 recommendations reviewed over the 27 months. Ten recom-
mendations were deferred and 8 recommendations were re-
submissions, thus 44 recommendations underwent analysis. The
subcommittee decisions were based on literature of varying levels
of evidence. There were 24 recommendations based on abstracts,
of which 14 (58%) were approved and 10 (42%) were rejected.
Eleven recommendations were based exclusively on abstracts, 7
(64%) of which were in favor of the new chemotherapy indica-
tion. Among the 20 recommendations not based on an abstract,
10 (50%) were approved and 10 (50%) were rejected. As a
comparison, published Randomized Control Trials were part of
the evidentiary base in 27 committee recommendations (61%).
Of these, 16 (59%) were in approval of a new chemotherapy
indication while 11 (41%) were opposed. CONCLUSION:
Research abstracts are commonly involved in evidence based
decision making for cancer drug funding. The rates of approving
cancer drugs for funding by the Ontario Cancer Drug Approval
Committee were similar among recommendations based on
abstracts and other levels of evidence.
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A COST-EFFECTIVENESS ANALYSIS OF HEPATITIS C
SCREENING AMONG IMMIGRANTS IN CANADA
Chen W1, Dinner K2,Wong T2, Heathcote J3, Krahn MD3
1University of Toronto,Toronto, ON, Canada, 2Public Health Agency
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OBJECTIVE: The costs and beneﬁts of hepatitis C (HCV) screen-
ing among immigrants need to be assessed since about 20% of
HCV cases in Canada are immigrants. METHODS: A decision
analytic model was developed to assess HCV screening among
immigrants. The prevalence of hepatitis C and distributions of
viral genotypes among immigrants were projected by the studies
related to HCV epidemiology in their home countries. Meta-
analyses of randomized trials were conducted to estimate the
effectiveness of current anti-viral therapy (pegylated interferon
plus ribavirin) in terms of genotype and disease stage. Survival
regression model and logistic regression model were applied to
project the transition probabilities for the disease progression by
identifying cohort studies on the natural history of chronic HCV.
The awareness of the disease, and the HCV incidence among
immigrants were estimated using PHAC’s surveillance data. The
costs associated with HCV screening test, anti-viral therapy,
and health care were estimated through published literatures.
Cost-effectiveness analysis for immigrants was further stratiﬁed
by world regions. RESULTS: HCV screening was associated with
an increase of life years (0.0013 years) and cost ($40.6) when
compared to no screening for all immigrants ($30,552 per addi-
tional life year). HCV screening for immigrants born in South
Asia was associated with longer life years (0.0108 years) and less
cost (-$50.6). HCV screening strategy for immigrants born in
Africa cost $8635 to gain one additional life year. No obvious
advantages of HCV screening were observed for immigrants
from other areas. CONCLUSION: The preliminary ﬁndings
suggest that it may be cost-effective to screen immigrants from
South Asia and Africa. However, further studies are needed to
conﬁrm our ﬁndings.
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THE EARLY CLINICAL AND ECONOMIC BENEFITS OF
ATORVASTATIN IN A CANADIAN SETTING
Merikle E1, Ramos É1, Kuznik A2, Botteman MF3
1Pﬁzer Canada Inc, Kirkland, QC, Canada, 2Pﬁzer Inc, New York, NY,
USA, 3PharMerit North America LLC, Bethesda, MD, USA
OBJECTIVE: Recent analyses from randomized clinical trials
(RCTs) indicate that, compared to generic simvastatin, atorvas-
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tatin treatment results in a reduction of cardiovascular (CV)
events during the ﬁrst year of treatment. This study was con-
ducted to estimate the early clinical and economic consequences
of initiating statin therapy with atorvastatin vs. simvastatin
from a Canadian societal perspective. METHODS: A cost-
consequence model was developed to estimate CV events and
costs over the ﬁrst 2 years of treatment associated with initiating
atorvastatin or simvastatin in a hypothetical cohort of 100,000
patients. Four groups of new users were considered, including
patients with: 1) diabetes; 2) multiple CV risk factors; 3) coro-
nary heart disease; and 4) acute coronary syndrome. RCT data
were used to estimate the CV event rate for each statin. CV
events included myocardial infarction, stroke, and revasculariza-
tion procedures. Corresponding direct costs (i.e., health care
utilisation, drug) were obtained from the Ontario Drug Beneﬁt
and Ontario Case Costing Initiative. Estimates of indirect costs
(loss of productivity) were obtained from Statistics Canada. All
costs were expressed in 2007 Canadian dollars. Multivariate
(Monte Carlo simulation) and univariate sensitivity analyses
were conducted on model assumptions. RESULTS: Within two
years of treatment initiation, the use of atorvastatin is predicted
to prevent 1648 CV events (95% CI: 1343–1956) per 100,000
new patients compared with simvastatin. Similarly, the cost of
CV events was reduced by $50.8 million (95% CI: $41.9–$59.8).
The incremental cost associated with atorvastatin treatment
was $31.3 million. This resulted in a net saving of $19.5 million
(95% CI: $10.7–$28.7). Savings were also observed across all
four groups considered. Results were sensitive to assumptions
regarding simvastatin efﬁcacy and levels of persistence. CON-
CLUSION: Based on this model, atorvastatin use is predicted to
result in cost savings to the Canadian society over simvastatin use
within 2 years of therapy initiation.
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FOLLOW-UPVISITS FOR PATIENTSWITH MAJOR DEPRESSIVE
DISORDER DURING INITIATION OF ANTIDEPRESSANT
TREATMENT
Chen SY, Hansen R, Maciejewski ML
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVE: Clinical guidelines recommend frequent follow-up
visits for patients initiating antidepressant treatment in order to
provide patient support, adjust dosage, and monitor side effects
and clinical response. We examined the frequency of follow-up
visits and factors associated with having guideline concordant
care during the acute phase of antidepressant treatment.
METHODS: Medical and prescription claims from a large
national health plan afﬁliated with i3 Innovus were analyzed
with a retrospective cohort design. Adults newly diagnosed with
major depressive disorder (n = 4447) from July 2000 to Decem-
ber 2002 who started a course of antidepressant treatment were
included. Follow-up visits during the ﬁrst three months after the
index prescription were counted, and patients were classiﬁed as
receiving guideline-concordant care if they had at least three
visits. Logistic regression was used to explore the predictors for
having the minimum number of recommended follow-up visits.
RESULTS: The mean number of follow-up visits during acute
phase treatment was 2.68. Only 43.4% of patients received
guideline-recommended level of follow-up care. In regression
analysis, an initial prescription from a psychiatrist was the stron-
gest predictor (OR = 2.66, 95% CI = 2.30–3.07). Receiving
psychotherapy, having comorbid anxiety, and having a lower
copayment was also positively associated with the probability of
guideline-recommended follow-up care (P < 0.05). CONCLU-
SION: Routine care for antidepressant management falls short of
guideline recommendations, especially in primary care. Modiﬁ-
able factors such as provider of care and copayments appear to
inﬂuence the likelihood of receiving guideline-concordant care.
DH2
IMPACT OF ADHERINGTO LIPID MANAGEMENT NATIONAL
GUIDELINE RECOMMENDATIONS ON CARDIOVASCULAR
EVENTS AND COSTS IN A MANAGED CARE POPULATION
Balu S1, Simko RJ1, Burge RT1, Quimbo R2, Cziraky MJ2
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc,
Wilmington, DE, USA
OBJECTIVE: Estimate the impact of adhering to lipid treatment
guidelines [National Cholesterol Education Program’s Third
Report on Detection, Evaluation, and Treatment of High Blood
Cholesterol and Adult Treatment Panel’s (NCEP-ATP III)] on
cardiovascular disease (CVD) events and associated costs in a
managed care population. METHODS: A retrospective analysis
was conducted using the HealthCore Integrated Research
Database on patients with laboratory values on low-density
lipoprotein-cholesterol (LDL-C), high-density lipoprotein-
cholesterol (HDL-C), & triglycerides (TG) between Janaury 1,
2003-December 31, 2005 [index date], no lipid therapy
6-months pre-index date, and minimum 12 months health plan
eligibility pre- and post-index date. Baseline lipid levels and the
ﬁrst post-index follow-up lipid panel (goal attainment), and risk
stratiﬁcation per NCEP-ATP III guidelines were used to catego-
rize patients as appropriately (AM) or inappropriately managed
(IAM). End points included counts of CVD events (ischemic
heart disease, peripheral vascular disease, stroke and related
occurrences and interventions) through Poisson regression and
associated annual total CVD-attributable costs ($CV) during
follow-up (multivariate generalized linear model regression)
between groups after controlling for baseline clinical and demo-
graphic differences. RESULTS: A total of 8176 patients (3493
AM; 4683 IAM) were identiﬁed. AM patients were signiﬁcantly
older [mean (SD) ages of 51.4 (9.1) vs. 50.0 (9.6); p < 0.01] and
comprised of fewer males (43.2% vs. 56.2%; p < 0.01). Baseline
Deyo-Charlson comorbidity scores were signiﬁcantly lower
among AM patients (0.20  0.44 vs. 0.32  0.56; p < 0.01).
During follow-up, AM patients had a 10% reduction in the
annual rate of CV events [Annual Event Rate (AER) = 0.90; 95%
CI, 0.86–0.93] as compared to IAM patients. A 12% reduction
in annual total $CV [Estimate: 0.88 (95% CI, 0.80–0.98) [$696
vs. $788; p = 0.02] was observed among AM patients versus
IAM patients. CONCLUSION: Comprehensive dyslipidemia
management reﬂecting clinical guideline treatment recommenda-
tions was associated with reductions in CVD events and $CV in
this managed care population.
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THE IMPACT OF DRUGVINTAGE ON PATIENT SURVIVAL:
A PATIENT-LEVEL APPROACH USING QUEBEC’S
PROVINCIAL HEALTH PLAN DATA
Lichtenberg F1,Van Audenrode M2, Grootendorst P3,
Latremouille-Viau D2, Lefebvre P2
1Columbia University, New York, NY, USA, 2Groupe d’analyse, Ltee,
Montreal, QC, Canada, 3University of Toronto,Toronto, ON, Canada
OBJECTIVE: There is much controversy about the value of new
medications and the substantial spending on R&D associated
with new treatments. The current study aimed at evaluating the
impact of drug innovation on longevity in three important
disease areas using patient-level data. METHODS: An analysis
of health claims from Quebec’s provincial health plan data
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